<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322309</url>
  </required_header>
  <id_info>
    <org_study_id>H-22530</org_study_id>
    <nct_id>NCT00322309</nct_id>
  </id_info>
  <brief_title>Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects</brief_title>
  <official_title>The Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to look at the safety of the medication Mirtazapine
      (Remeron) in people who have cocaine dependence and depression. Hypotheses I. Cocaine usage
      will be less in the mirtazapine treatment group (MG) than in the control group (CG). II. A
      greater increase in Clinician Global Impression (CGI) score will be observed in the MG than
      in the CG. Secondary Hypotheses: I. A greater decrease in Hamilton Rating Scale for
      Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) scores will be observed in
      the MG than in the CG. II. A greater decrease in HIV risk behaviors will be observed in the
      MG than in the CG. III. A greater improvement in sleep structure will be observed in the MG
      than in the CG. IV. The proportion of subjects experiencing severe adverse drug reactions
      that necessitate termination from the study by one of the study clinicians will not differ
      between the MG and CG. V. Retention will be greater in MG than in CG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine dependence is a significant public health problem associated with serious medical,
      psychiatric, social and economic consequences. It is generally accepted that the euphoria
      associated with cocaine use is a result of its action on reward pathways via antagonist
      properties at the dopamine transporter site; cocaine also inhibits reuptake of serotonin and
      norepinephrine. These actions are thought to underlie cocaine's potent reinforcing
      properties. With prolonged use, cocaine may deplete these neurotransmitters, affect
      postsynaptic receptor density, and elicit an overall dysregulation of these neurotransmitter
      systems. These longer term consequences may account for the post-cocaine depressive symptoms
      often claimed by cocaine users to contribute to relapse. Treatment for cocaine dependence at
      the present is primarily psychosocial/behavioral. Currently there is no pharmacological agent
      approved for treatment of cocaine dependence in conjunction with psychosocial interventions.
      Several drugs currently approved for other indications are presently under consideration for
      treatment of cocaine dependence based on their known mechanisms and sites of action. Current
      approaches include strategies to (1) block the effects of cocaine, (2) substitutes for
      cocaine, (3) reduce craving or enhance the addict's ability to manage his/her response to
      craving, and (4) treat underlying conditions (or consequences of cocaine use) that may
      predispose toward dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ln Benzoylecgonine Concentration</measure>
    <time_frame>Week 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Clinical Global Impression Observer (CGI-O)Comparison for Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Clinician's overall assessment of the subjects global functioning including the severity of the subject's cocaine use, cocaine seeking, use of other drugs, psychiatric symptoms, medical problems, maladaptive family/social coping, and coping with issues related to employment, housing, and legal issues. Totals range between 7 (for none) to 56 for most severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>Week 11</time_frame>
    <description>Subjects are assessed on 24 characteristics of depressive disorders. Scale scores may range from 0 for no depressive symptoms to 75.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pill Count</measure>
    <time_frame>Weeks 1 to 11</time_frame>
    <description>Percentage of medication capsules administered based on the ratio of the number of capsules administered to the total number dispensed for entire period during which subjects were in treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Urines Positive for Riboflavin</measure>
    <time_frame>Weeks 1-11</time_frame>
    <description>This measure of adherence was determined by finding the percent of total urines examined that were positive for riboflavin, which had been added to each medication tablet.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Mirtazapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirtazapine administration as follows:
Days 1-4 15mg of mirtazapine daily Days 5-9 30mg of mirtazapine daily Days 10-78 45mg of mirtazapine daily Days 79-81 30mg of mirtazapine daily Days 82-84 15mg of mirtazapine daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo given daily days 1-84</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84</description>
    <arm_group_label>Placebo- Sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
    <arm_group_label>Mirtazapine</arm_group_label>
    <other_name>Remeron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis
             of cocaine dependence.

          -  HAM-D score of 12 or above and history of autonomous depression, defined as meeting
             DSM-IV criteria for major depression or dysthymic disorder during any lifetime period
             of abstinence of 30 days or longer.

          -  At least one urine toxicology positive for cocaine benzoylecgonine (BE) over the
             consecutive two-week baseline screening period during which 6 urine samples have been
             obtained

          -  Males and non-pregnant, non-nursing females, 18-64 years of age (inclusive).

          -  Individuals able to give written informed consent and willing to comply with all study
             procedures.

        Exclusion Criteria:

          -  Any Axis I diagnosis that, in the opinion of the Principal Investigator, may interfere
             with the course of the trial.

          -  Physiological dependence on alcohol or opiates requiring medical detoxification.

          -  A medical or neurological illness that in the clinical judgment of the investigator
             would make study compliance difficult or contraindicate the use of mirtazapine.

          -  Any clinically significant abnormal lab values or liver function tests (LFTs) which
             are greater than 3 times the normal limit.

          -  The need or intention to use concurrently with or within four weeks prior to study
             drug administration, any of the following medications: monoamine oxidase inhibitors
             and/or sibutramine. In addition, other medications such as alpha2-agonists and
             medications which affect the enzymes Cytochrome P450 1A2 (CYP1A2), Cytochrome P450 2D6
             (CYP2D6), Cytochrome P450 3A4 (CYP3A4) (as inhibitors, substrates, or inducers), and
             serotonin modulators should be used with caution. The research physician will decide
             on this issue. A listing of these substances may be found in Appendix I.

          -  Females of childbearing potential who do NOT agree to use a medically acceptable
             method of birth control (barrier, intrauterine device (IUD), oral or depot
             contraceptive medication, or complete abstinence).

          -  Positive pregnancy test.

          -  Breastfeeding

          -  Known drug allergy or sensitivity to mirtazapine.

          -  Participation in an investigational drug or device study within 1 month of enrollment
             in the present study.

          -  Enrollment in an opiate-substitution (i.e., methadone, levo acetyl methadol (LAAM))
             treatment program within 45 days of enrolling in the present study.

          -  Individuals having taken LAAM, methadone or naltrexone within 14 days of enrollment in
             the present study.

          -  Individuals who, in the clinical judgment of the Investigator, are actively and
             acutely suicidal.

          -  Subjects, who in the opinion of the investigator, have a medical condition that may
             interfere with study assessments and/or put them at undue risk.

          -  Subjects, who in the opinion of the investigator, will have difficulty complying with
             study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Afshar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2006</study_first_submitted>
  <study_first_submitted_qc>May 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2006</study_first_posted>
  <results_first_submitted>July 23, 2013</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Substance Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at the Boston University Psychiatry Associates Clinical Studies Unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mirtazapine</title>
          <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo given daily days 1-84</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mirtazapine</title>
          <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects received matched placebo capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="5.6"/>
                    <measurement group_id="B2" value="47.2" spread="6.7"/>
                    <measurement group_id="B3" value="45.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ln Urine Benzoylecgonine Conc</title>
          <description>Baseline urine LB BE concentrations were obtained during the screening sessions.</description>
          <units>ln (ng/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.3" spread="1.7"/>
                    <measurement group_id="B2" value="9.1" spread="2.4"/>
                    <measurement group_id="B3" value="9.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ln Benzoylecgonine Concentration</title>
        <time_frame>Week 11</time_frame>
        <population>Data was analyzed for all subjects who provided data for the second assessment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirtazapine</title>
            <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received matched placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Ln Benzoylecgonine Concentration</title>
          <population>Data was analyzed for all subjects who provided data for the second assessment visit.</population>
          <units>ln (ng/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="1.8"/>
                    <measurement group_id="O2" value="7.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that there would be no significant difference between the two treatment groups for benzoylecgonine data collected for Week 11.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Clinical Global Impression Observer (CGI-O)Comparison for Week 11</title>
        <description>Clinician's overall assessment of the subjects global functioning including the severity of the subject's cocaine use, cocaine seeking, use of other drugs, psychiatric symptoms, medical problems, maladaptive family/social coping, and coping with issues related to employment, housing, and legal issues. Totals range between 7 (for none) to 56 for most severe.</description>
        <time_frame>Week 11</time_frame>
        <population>Data was analyzed fof all subjects for whom data from the second evaluation visit was available</population>
        <group_list>
          <group group_id="O1">
            <title>Mirtazapine</title>
            <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received matched placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Clinical Global Impression Observer (CGI-O)Comparison for Week 11</title>
          <description>Clinician's overall assessment of the subjects global functioning including the severity of the subject's cocaine use, cocaine seeking, use of other drugs, psychiatric symptoms, medical problems, maladaptive family/social coping, and coping with issues related to employment, housing, and legal issues. Totals range between 7 (for none) to 56 for most severe.</description>
          <population>Data was analyzed fof all subjects for whom data from the second evaluation visit was available</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="4.8"/>
                    <measurement group_id="O2" value="23.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that means scores for the CGI-O would not differ significantly for these values obtained in the final treatment week, Week 11.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Rating Scale</title>
        <description>Subjects are assessed on 24 characteristics of depressive disorders. Scale scores may range from 0 for no depressive symptoms to 75.</description>
        <time_frame>Week 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirtazepine</title>
            <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale</title>
          <description>Subjects are assessed on 24 characteristics of depressive disorders. Scale scores may range from 0 for no depressive symptoms to 75.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="4.7"/>
                    <measurement group_id="O2" value="6.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It hypothesized that the two treatment groups would not differ significantly with respect to the total HAM-D scores obtained in the final week of the study (Week 11).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>This analysis involves a between group comparison.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pill Count</title>
        <description>Percentage of medication capsules administered based on the ratio of the number of capsules administered to the total number dispensed for entire period during which subjects were in treatment.</description>
        <time_frame>Weeks 1 to 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirtazapine</title>
            <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo given daily days 1-84</description>
          </group>
        </group_list>
        <measure>
          <title>Pill Count</title>
          <description>Percentage of medication capsules administered based on the ratio of the number of capsules administered to the total number dispensed for entire period during which subjects were in treatment.</description>
          <units>Percentage of dispensed capsules</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="21"/>
                    <measurement group_id="O2" value="91" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that there would be no significant difference in the mean percentage of capsules of those dispensed between the two groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Percent of capsules administered does not differ significantly between the two groups.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>18</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Urines Positive for Riboflavin</title>
        <description>This measure of adherence was determined by finding the percent of total urines examined that were positive for riboflavin, which had been added to each medication tablet.</description>
        <time_frame>Weeks 1-11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirtazapine</title>
            <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo given daily days 1-84</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Urines Positive for Riboflavin</title>
          <description>This measure of adherence was determined by finding the percent of total urines examined that were positive for riboflavin, which had been added to each medication tablet.</description>
          <units>Percentage of total urines examined</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" spread="7.6"/>
                    <measurement group_id="O2" value="93.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that there would not be a significant difference between the two groups in the mean percent of urines positive for riboflavin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.5</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mirtazapine Daily: Days 1-4 15mg Days 5-9 30mg Mirtazapine</title>
          <description>Mirtazapine daily:
Days 1-4 15mg Days 5-9 30mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fainting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maryam Afshar, MD</name_or_title>
      <organization>BUPA CSU, Boston University School of Medicine</organization>
      <phone>617-414-1990</phone>
      <email>maryam.afshar@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

